Supplementary Figure S1. Inhibitor of PAK1 does not suppress anaplastic thyroid cancer cell proliferation neither alone nor in combination with lenvatinib. [A] 8505C cells were seeded in 96 well plates at a density of 5000 cells per well. The next day cells were exposed to increasing concentrations of IPA-3 for 72 hrs. At the end of treatment, MTT assay was performed according to standard procedure described in methods section. Each point represents six replicates. [B] 8505C thyroid cancer cells were treated with indicated concentrations of either lenvatinib or IPA-3 or combinations of lenvatinib with IPA-3 for 3 days. Cell proliferation assay using MTT was conducted.